Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5112 Target Snapshot

Gamma-aminobutyric acid receptor subunit alpha-5 · SINGLE PROTEIN · Homo sapiens

622Compounds
50Assays
7Approved Drugs
538.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt P31644. Use UniProt P31644 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P31644 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Gamma-aminobutyric acid receptor subunit alpha-5 as ChEMBL target CHEMBL5112, mapped to UniProt P31644. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Gamma-aminobutyric acid receptor subunit alpha-5
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL5112
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P31644
Gamma-aminobutyric acid receptor subunit alpha-5
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Gamma-aminobutyric acid receptor subunit alpha-5 is the right protein anchor across sources, using UniProt P31644 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelGamma-aminobutyric acid receptor subunit alpha-5
UniProt AccessionP31644
Component TypeProtein
Sequence Length462 aa

Gamma-aminobutyric acid receptor subunit alpha-5

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Gamma-aminobutyric acid receptor subunit alpha-5, mapped to UniProt P31644. Sequence length is 462 aa.

Mapped IDP31644
Review nameGamma-aminobutyric acid receptor subunit alpha-5
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

7
Approved
5
Phase II
1
Phase I
Assay Mix

Activity Type Distribution

IC5019.0
KI481.0
EC5017.0
KD21.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3681588 10.0 Ki 0.1 Preclinical
CHEMBL3681586 9.7 Ki 0.2 Preclinical
CHEMBL3676421 9.52 Ki 0.3 Preclinical
CHEMBL3676424 9.52 Ki 0.3 Preclinical
CHEMBL3676425 9.52 Ki 0.3 Preclinical
CHEMBL3676426 9.52 Ki 0.3 Preclinical
CHEMBL3676436 9.52 Ki 0.3 Preclinical
CHEMBL3681585 9.52 Ki 0.3 Preclinical
CHEMBL5268764 9.52 Ki 0.3 Preclinical
CHEMBL3639753 9.4 Ki 0.4 Preclinical
Distribution

pChEMBL Value Distribution

1
5.0
5
5.5
22
6.0
30
6.5
81
7.0
137
7.5
119
8.0
81
8.5
39
9.0
8
9.5
pChEMBL
Approved Drugs

Approved Drugs

FLUMAZENIL
CHEMBL407
Approved 1991
ALPRAZOLAM
CHEMBL661
Approved 1981
TRIAZOLAM
CHEMBL646
Approved 1978
DIAZEPAM
CHEMBL12
Approved 1963
Assay Landscape

Assay Landscape

50
Total Assays
510
Tested Compounds
1
Assay Types
Binding — 50 assays, 510 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 38 488 8.0
cell-based format 8 10 6.8
assay format 2 11 7.8
tissue-based format 2 1 8.5

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine